Timing of thoracic radiotherapy is more important than dose intensification in patients with limited-stage small cell lung cancer: a parallel comparison of two prospective studies
Creators
- 1. Department of Radiation Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang Provincial Key Laboratory of Radiation Oncology, Institute of Cancer Research and Basic Medical Sciences, Chinese Academy of Sciences, Hangzhou (China)
- 2. Department of Radiation Oncology, Cancer Hospital of Fudan University, Shanghai (China)
- 3. Department of Radiation Oncology, Hangzhou Cancer Hospital, Hangzhou (China)
- 4. Department of Radiation Oncology, The First affiliated Hospital of Sun Yat-sen University, Guangzhou (China)
Description
The optimal radiotherapy dose/fraction for limited-stage small cell lung cancer (SCLC) is undefined. Our objectives were to compare efficacy between hyperfractionated thoracic radiotherapy (TRT; 1.5 Gy 2 times per day [bid] in 30 fractions) and hypofractionated TRT (2.5 Gy once per day [qd] in 22 fractions), and to explore prognostic factors influencing the prognosis, such as the timing of TRT. Patients enrolled in two independent prospective studies were combined and analyzed. The primary endpoint was local/regional control (LRC). The prognosis was analyzed using the Cox proportional hazards regression model. Ninety-two and 96 patients were treated with hyperfractionated TRT and hypofractionated TRT, respectively. The 1‑ and 2‑year LRC rates of the two arms were 82.1 and 60.7%, and 84.9 and 68.8% (P = 0.27), respectively. The median overall survival (OS) times (months) were 28.3 (95% confidence interval, CI 16.4–40.1) and 22.0 (95% CI 16.4–27.5), while the 1‑year, 3‑year, and 5‑year OS rates were 85.2, 40.8, and 27.1%, and 76.9, 34.3, and 26.8% (P = 0.37), respectively. Using a multivariate Cox regression study, time (days) from the initiation of chemotherapy to TRT (TCT) ≤43 was associated with improved LRC (hazard radio, HR 0.39, 95% CI 0.20–0.76; P = 0.005). Time (days) from the start of chemotherapy to the end of TRT (SER) ≤63 (HR 0.50, 95% CI 0.32–0.80; P = 0.003) and prophylactic cranial irradiation (HR 0.43; 95% CI 0.29–0.63; P = 0.000) were favorably related to OS. Grade 2/3 acute radiation esophagitis was observed in 37.0 and 17.7% of patients in the hyperfractionated and hypofractionated arms, respectively (P = 0.003). Both hyperfractionated and hypofractionated TRT schedules achieved good LRC and OS for patients with limited-stage SCLC in this study. Keeping TCT ≤43 and SER ≤63 resulted in a better prognosis. The incidence of acute esophagitis was significantly higher in the hyperfractionated arm.
Availability note (English)
Available from: http://dx.doi.org/10.1007/s00066-019-01539-1Additional details
Identifiers
Publishing Information
- Journal Title
- Strahlentherapie und Onkologie
- Journal Volume
- 196
- Journal Issue
- 2
- Journal Page Range
- p. 172-181
- ISSN
- 0179-7158
- CODEN
- STONE4
INIS
- Country of Publication
- Germany
- Country of Input or Organization
- Germany
- INIS RN
- 51042424
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- CARCINOMAS; CELL PROLIFERATION; CHEMOTHERAPY; CLINICAL TRIALS; COMPARATIVE EVALUATIONS; DELAYED RADIATION EFFECTS; EXTERNAL BEAM RADIATION THERAPY; FRACTIONATED IRRADIATION; GY RANGE 01-10; GY RANGE 10-100; LUNGS; MULTIVARIATE ANALYSIS; RADIATION DOSES; REGRESSION ANALYSIS; SIDE EFFECTS; SURVIVAL CURVES; TOXICITY
- Descriptors DEC
- ABSORBED DOSE RANGE; BIOLOGICAL EFFECTS; BIOLOGICAL RADIATION EFFECTS; BODY; DISEASES; DOSES; EVALUATION; GY RANGE; IRRADIATION; MATHEMATICS; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; ORGANS; RADIATION DOSE RANGES; RADIATION EFFECTS; RADIOLOGY; RADIOTHERAPY; RESPIRATORY SYSTEM; STATISTICS; TESTING; THERAPY